4.5 Article

Investigating the impact of TB case-detection strategies and the consequences of false positive diagnosis through mathematical modelling

Journal

BMC INFECTIOUS DISEASES
Volume 18, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12879-018-3239-x

Keywords

Tuberculosis; Screening; False positive diagnosis; Mathematical modelling

Funding

  1. MRC [MR/P002404/1] Funding Source: UKRI
  2. Medical Research Council [MR/P002404/1] Funding Source: Medline
  3. United States Agency for International Development [GHN-A-00-08-00004-00] Funding Source: Medline

Ask authors/readers for more resources

Background: Increasing case notifications is one of the top programmatic priorities of National TB Control Programmes (NTPs). To find more cases, NTPs often need to consider expanding TB case-detection activities to populations with increasingly low prevalence of disease. Together with low-specificity diagnostic algorithms, these strategies can lead to an increasingly high number of false positive diagnoses, which has important adverse consequences. Methods: We apply TIME, a widely-used country-level model, to quantify the expected impact of different case-finding strategies under two scenarios. In the first scenario, we compare the impact of implementing two different diagnostic algorithms (higher sensitivity only versus higher sensitivity and specificity) to reach programmatic screening targets. In the second scenario, we examine the impact of expanding coverage to a population with a lower prevalence of disease. Finally, we explore the implications of modelling without taking into consideration the screening of healthy individuals. Outcomes considered were changes in notifications, the ratio of additional false positive to true positive diagnoses, the positive predictive value (PPV), and incidence. Results: In scenario 1, algorithm A of prolonged cough and GeneXpert yielded fewer additional notifications compared to algorithm B of any symptom and smear microscopy (n = 4.0 K vs 13.8 K), relative to baseline between 2017 and 2025. However, algorithm A resulted in an increase in PPV, averting 2.4 K false positive notifications thus resulting in a more efficient impact on incidence. Scenario 2 demonstrated an absolute decrease of 11% in the PPV as intensified case finding activities expanded into low-prevalence populations without improving diagnostic accuracy, yielding an additional 23 K false positive diagnoses for an additional 1.3 K true positive diagnoses between 2017 and 2025. Modelling the second scenario without taking into account screening amongst healthy individuals overestimated the impact on cases averted by a factor of 6. Conclusion: Our findings show that total notifications can be a misleading indicator for TB programme performance, and should be interpreted carefully. When evaluating potential case-finding strategies, NTPs should consider the specificity of diagnostic algorithms and the risk of increasing false-positive diagnoses. Similarly, modelling the impact of case-finding strategies without taking into account potential adverse consequences can overestimate impact and lead to poor strategic decision-making.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Immunology

Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case

Sonali Kochhar, Draurio Barreira, Pauline Beattie, Marco Cavaleri, Alejandro Cravioto, Mike W. Frick, Ann M. Ginsberg, Ian Hudson, David C. Kaslow, Sherry Kurtz, Christian Lienhardt, Shabir A. Madhi, Christopher Morgan, Yalda Momeni, Deepali Patel, Helen Rees, Taryn Rogalski-Salter, Alexander Schmidt, Boitumelo Semete-Makokotlela, Gerald Voss, Richard G. White, Matteo Zignol, Birgitte Giersing

Summary: Currently, there is a lack of formal mechanisms or systematic approaches to provide vaccine developers with anticipated evidence to support global policy recommendations. To address this issue, the World Health Organization (WHO) is evaluating a new strategic alignment tool called Evidence Considerations for Vaccine Policy (ECVP). The aim of ECVPs is to bridge the gap in evidence needs and reduce the risk of delays between vaccine recommendation and use.

VACCINE (2022)

Article Multidisciplinary Sciences

Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India

Rebecca C. Harris, Matthew Quaife, Chathika Weerasuriya, Gabriela B. Gomez, Tom Sumner, Fiammetta Bozzani, Richard G. White

Summary: The study evaluated the impact and cost-effectiveness of adolescent vaccination with the M72/AS01(E)-like vaccine in South Africa and India. The results showed that the vaccine was highly cost-effective in both settings. Additionally, vaccinating 50% of 18 year-olds was found to be similarly cost-effective to vaccinating 80% of 15 year-olds and more cost-effective than vaccinating 80% of 10 year-olds.

NATURE COMMUNICATIONS (2022)

Article Medicine, General & Internal

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

Allison Portnoy, Rebecca A. Clark, Matthew K. Quaife, Chathika K. Weerasuriya, Christinah Mukandavire, Roel Bakker, Arminder K. Deol, Shelly Malhotra, Nebiat Gebreselassie, Matteo Zignol, So Yoon Sim, Raymond C. W. G. Hutubessy, Ines Garcia A. Baena, Nobuyuki Nishikiori, Mark Jit, Richard G. White, Nicolas A. Menzies

Summary: This study evaluates the future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries. The findings suggest that TB vaccination would be highly impactful and cost-effective, with significant health and economic benefits.

PLOS MEDICINE (2023)

Article Infectious Diseases

Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package-hmer

Danny Scarponi, Andrew Iskauskas, Rebecca A. Clark, Ian Vernon, Trevelyan J. McKinley, Michael Goldstein, Christinah Mukandavire, Arminder Deol, Chathika Weerasuriya, Roel Bakker, Richard G. White, Nicky McCreesh

Summary: Infectious disease models are used by epidemiologists to understand transmission dynamics, predict interventions, and improve disease understanding. However, as the complexity of these models increases, calibration to data becomes more challenging. This study introduces a new software, hmer, which efficiently calibrates complex models for tuberculosis vaccines to over 100 countries. The results show that hmer is a useful tool for epidemiologists to calibrate models and improve predictions.

EPIDEMICS (2023)

Article Critical Care Medicine

Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment

Molebogeng X. Rangaka, Mike Frick, Gavin Churchyard, Alberto L. Garcia-Basteiro, Mark Hatherill, Willem Hanekom, Philip C. Hill, Yohhei Hamada, Matthew Quaife, Johan Vekemans, Richard G. White, Frank Cobelens

Summary: This paper discusses the urgent need for new tuberculosis vaccines and improved tuberculosis preventive treatment (TPT) regimens. It examines how HIV vaccine trials have incorporated preventive treatment and proposes trial designs that integrate TPT. The considerations for each design in terms of trial validity, efficiency, participant safety, and ethics are summarized.

LANCET RESPIRATORY MEDICINE (2023)

Article Public, Environmental & Occupational Health

Cost-effectiveness of tuberculosis infection prevention and control interventions in South African clinics: a model-based economic evaluation informed by complexity science methods

Fiammetta Maria Bozzani, Nicky McCreesh, Karin Diaconu, Indira Govender, Richard G. White, Karina Kielmann, Alison D. Grant, Anna Vassall

Summary: An economic evaluation conducted in two clinics in South Africa showed that tuberculosis infection prevention and control measures, including improving ventilation and maximizing the use of existing systems, are cost-effective and should be implemented within the country's health system.

BMJ GLOBAL HEALTH (2023)

Article Infectious Diseases

Measuring indirect transmission-reducing effects in tuberculosis vaccine efficacy trials: why and how?

Kristin N. Nelson, Gavin Churchyard, Frank Cobelens, Willem A. Hanekom, Philip C. Hill, Benjamin Lopman, Vidya Mave, Molebogeng X. Rangaka, Johan Vekemans, Richard G. White, Emily B. Wong, Leonardo Martinez, Alberto L. Garcia-Basteiro

Summary: Tuberculosis is a leading bacterial cause of death worldwide. Several vaccine candidates are currently in clinical trials to prevent tuberculosis in adolescents and adults. However, current trial designs do not provide information on the overall effect of introducing a vaccine program, including indirect effects. Understanding these effects is crucial for policymakers considering tuberculosis vaccination programs.

LANCET MICROBE (2023)

Article Medicine, General & Internal

New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01(E) and BCG-revaccination

Rebecca A. Clark, Chathika K. Weerasuriya, Allison Portnoy, Christinah Mukandavire, Matthew Quaife, Roel Bakker, Danny Scarponi, Rebecca C. Harris, Kirankumar Rade, Sanjay Kumar Mattoo, Dheeraj Tumu, Nicolas A. Menzies, Richard G. White

Summary: The potential health and economic impact of M72/AS01(E) and BCG-revaccination in India were evaluated. The results showed that M72/AS01(E) vaccine could prevent more tuberculosis cases and deaths compared to BCG-revaccination, and almost all scenarios were cost-effective. However, there is uncertainty regarding the vaccine characteristics that requires further investment.

BMC MEDICINE (2023)

Article Public, Environmental & Occupational Health

Improving the quality of the Global Burden of Disease tuberculosis estimates from the Institute for Health Metrics and Evaluation

Peter J. Dodd, Christopher Finn Mcquaid, Prasada Rao, Ibrahim Abubakar, Nimalan Arinaminpathy, Anna Carnegie, Frank Cobelens, David Dowdy, Kathy Fiekert, Alison D. Grant, Jing Wu, Faith Nekabari Nfii, Nabila Shaikh, Rein M. G. J. Houben, Richard G. White

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2023)

Editorial Material Immunology

An Aspiration to Radically Shorten Phase 3 Tuberculosis Vaccine Trials

Philip C. Hill, Frank Cobelens, Leonardo Martinez, Marcel A. Behr, Gavin Churchyard, Tom Evans, Andrew J. Fiore-Gartland, Alberto L. Garcia-Basteiro, Willem Hanekom, Molebogeng X. Rangaka, Johan Vekemans, Richard G. White

Summary: The development of a new tuberculosis vaccine is crucial, but the traditional development pathway is a major obstacle. By increasing sample size, simplifying screening criteria and procedures, and strengthening site capacity, phase 3 tuberculosis vaccine trials can be significantly shortened.

JOURNAL OF INFECTIOUS DISEASES (2023)

Letter Immunology

Reply to McShane

Philip C. Hill, Frank Cobelens, Leonardo Martinez, Alberto L. Garcia-Basteiro, Marcel A. Behr, Molebogeng X. Rangaka, Gavin Churchyard, Tom Evans, Willem Hanekom, Richard G. White

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Medicine, General & Internal

The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study

Allison Portnoy, Jean-Louis Arcand, Rebecca A. A. Clark, Chathika K. K. Weerasuriya, Christinah Mukandavire, Roel Bakker, Edith Patouillard, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. G. White, Nicolas A. A. Menzies

Summary: This study aimed to estimate the impact of introducing novel TB vaccines on GDP growth in 105 LMICs. The results showed that introducing new TB vaccines could increase economic growth in these countries, with a more significant effect in countries with higher current TB incidence.

PLOS MEDICINE (2023)

Article Public, Environmental & Occupational Health

The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries

Allison Portnoy, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Matthew Quaife, Roel Bakker, Ines Garcia Baena, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies

Summary: Introducing novel TB vaccines can reduce the financial burden and household economic risks for low-income individuals with tuberculosis. The health benefits of the vaccines are greatest for the lower income quintiles, reducing income-based inequalities in TB outcomes.

BMJ GLOBAL HEALTH (2023)

Article Public, Environmental & Occupational Health

Is neglect of self-clearance biasing TB vaccine impact estimates?

Danny Scarponi, Rebecca A. Clark, Chathika Krishan Weerasuriya, Jon Emery, Rein M. G. J. Houben, Richard White, Nicky McCreesh

Summary: Recent research suggests that self-clearance of Mycobacterium tuberculosis infection may be common, which could impact the potential impact of new tuberculosis vaccines. This study found that the inclusion of self-clearance in mathematical models increased the estimated relative reduction in incidence for vaccines effective only in uninfected individuals, but had variable effects on vaccines effective only in infected individuals. The inclusion of self-clearance had minimal impact on vaccines that work regardless of infection status.

BMJ GLOBAL HEALTH (2023)

Article Public, Environmental & Occupational Health

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

Rebecca A. Clark, Christinah Mukandavire, Allison Portnoy, Chathika K. Weerasuriya, Arminder Deol, Danny Scarponi, Andrew Iskauskas, Roel Bakker, Matthew Quaife, Shelly Malhotra, Nebiat Gebreselassie, Matteo Zignol, Raymond C. W. Hutubessy, Birgitte Giersing, Mark Jit, Rebecca C. Harris, Nicolas A. Menzies, Richard G. White

Summary: The study estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) under different delivery scenarios. It found that introducing new tuberculosis vaccines can significantly reduce cases and deaths, and a one-off vaccination campaign is crucial for rapid impact.

LANCET GLOBAL HEALTH (2023)

No Data Available